CAR vs LEGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CAR is the larger of the two ($4.57B market cap): the incumbent the market prices for continued execution (33.98x forward earnings, beta 2.03). LEGN is the smaller challenger ($2.98B), cheaper on forward earnings (29.10x): more room to run, but more to prove. On the numbers, LEGN leads on both counts: faster expected revenue growth (18% vs 1%) and a lower forward P/E (29.1x vs 33.98x). The case for CAR rests on its own driver (Fleet utilization and pricing recovery): if you believe in that, CAR fits; if you believe in what the numbers show today, LEGN does.

CAR vs LEGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCARLEGNWhat it tells you
Market cap$4.57B$2.98BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E33.9829.10Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.030.55Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range6% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: LEGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CAR and LEGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAR and LEGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAR and LEGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Avis Budget Group (CAR) do?

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

What does Legend Biotech (LEGN) do?

Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative. Ingrid Zhang became chief executive effective September 15, 2026.

Full LEGN guide

CAR vs LEGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.
  • LEGN drivers: CARVYKTI commercial ramp; Move to earlier lines of therapy.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. For LEGN, legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine.

CAR or LEGN: which should you pick?

If the story you believe is CAR's (Fleet utilization and pricing recovery), CAR is the more direct way to own it; if it is LEGN's (CARVYKTI commercial ramp), LEGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAR and LEGN guides.

CAR vs LEGN: the full fundamentals

CAR. CAR still does not screen on a trailing price-to-earnings basis because trailing EPS is negative (about -$23), so investors lean on forward earnings (about 34x after the November rally) and enterprise-value-to-EBITDA (about 21.5x on trailing EBITDA of roughly $1.49 billion, an EV dominated by fleet debt). At about 0.39x sales and with negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's disclosures through the third quarter of 2026 and consensus estimates as of November 20, 2026.

LEGN. LEGN's revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $710 million of Q3 2026 global net trade sales. At about $15.42 on November 20, 2026 the ADRs trade near 2.2 times trailing sales and about 29 times forward EPS estimates, close to their 52-week low of $15.36, because slowing US growth and competition from anito-cel and bispecifics now weigh on how long the ramp lasts. The 14 covering analysts carry a consensus buy rating and a mean target near $41, though RBC trimmed its target to $50 after the Q3 report and UBS had already cut to $24.

Headline figures (approximate, November 2026): CAR shows revenue (ttm) ~$11.6B, revenue (q3 2026) ~$3.44B, down ~2% YoY, q3 2026 eps (actual vs est.) $5.15 vs ~$8.31, adjusted ebitda Q3 2026 ~$513M (-8%); FY2026 guide ~$850M; LEGN shows revenue (ttm, collaboration/license) ~$1.36B, q3 2026 total revenue ~$359.5M (up ~32% YoY), q3 2026 carvykti net trade sales ~$710M (up ~36% YoY; US +19%, ex-US +86%), q3 2026 net income ~$51.7M.

The bottom line: CAR vs LEGN

CAR and LEGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CAR and LEGN exposure against your real portfolio. It is not an investment adviser.

Wondering how CAR or LEGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Avis Budget Group

Ask Walnut's AI anything about CAR and see how it fits what you own.

FAQ

What is the difference between CAR and LEGN?

+

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CAR or LEGN the better stock?

+

Neither is universally better. CAR is the larger incumbent; LEGN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CAR or LEGN?

+

On forward P/E (as of November 2026), CAR trades at 33.98x and LEGN at 29.10x, so LEGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CAR and LEGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CAR vs LEGN?

+

CAR: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. Negative stockholders' equity leaves little cushion if losses continue, and refinancing large maturities is an ongoing requirement, not a one-time event. Competition from Enterprise, Hertz, Sixt and peer-to-peer platforms limits pricing power, and further EV or fleet writedowns remain possible. Results are also seasonal, with the first quarter typically the weakest, which can exaggerate headline losses. Execution against estimates has been poor in 2026: Q1 EPS of -$8.01 came in below the -$7.50 consensus, Q2 EPS of $0.98 roughly halved expectations, and Q3 EPS of $5.15 fell well short of about $8.31, with the full-year EBITDA outlook cut to the low end of its range. Revenue was down about 2 percent year over year in Q3, so the earnings recovery depends on cost and fleet discipline more than demand growth, and softer air travel is a direct headwind. The share price has swung widely, rising about 27 percent in the month to November 20, 2026 after falling about 32 percent in the three months to mid-October, and it now trades above the average analyst target of about $110. LEGN: Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. Gilead's anito-cel, another BCMA CAR-T, has an FDA decision date of December 23, 2026, and Legend has estimated that about 59% of the US CARVYKTI market sits in the fourth-line-plus segment where anito-cel is expected to be labeled; UBS also flagged J&J's Tec-Dara as a threat in earlier lines. US growth already slowed to 19% in Q3 2026 from 32% the quarter before, and Q4 consensus sat at the high end of management's scenarios, so further deceleration is a live risk. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company only reached quarterly GAAP profit in Q2 2026 and its trailing earnings are roughly breakeven, so any sales miss, pricing pressure, or safety signal can move the stock sharply, as the 18% drop on November 10 showed. A new chief executive took over in September 2026. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CAR or LEGN; figures are approximate and dated (as of November 2026). Verify current data before investing.